Arcellx Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

ArcellxDer Gewinn des Unternehmens wird voraussichtlich um 6.4% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 22.5% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich sinken um 7.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -15.8% betragen.

Wichtige Informationen

-6.4%

Wachstumsrate der Gewinne

-7.2%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	22.5%
Zukünftige Eigenkapitalrendite	-15.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Oct 28

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Sep 10

There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Massive 28% Price Jump

Sep 05

We're Interested To See How Arcellx (NASDAQ:ACLX) Uses Its Cash Hoard To Grow

Aug 10

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Jul 12

News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts

Jun 01

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic

May 14

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

May 12

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 01

Arcellx: Navigating The CAR T-Cell Revolution

Jan 30

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Nov 18

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 10

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ACLX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	177	-134	-99	-46	11
12/31/2025	120	-136	-99	-103	17
12/31/2024	119	-90	-76	-74	16
9/30/2024	156	-40	4	21	N/A
6/30/2024	145	-54	-43	-20	N/A
3/31/2024	132	-51	-33	-6	N/A
12/31/2023	110	-71	186	208	N/A
9/30/2023	47	-130	104	122	N/A
6/30/2023	32	-183	105	115	N/A
3/31/2023	18	-190	113	115	N/A
12/31/2022	N/A	-189	-102	-99	N/A
9/30/2022	N/A	-170	-99	-93	N/A
6/30/2022	N/A	-95	-94	-89	N/A
3/31/2022	N/A	-80	-83	-77	N/A
12/31/2021	N/A	-65	-60	-54	N/A
9/30/2021	N/A	-53	-42	-40	N/A
12/31/2020	N/A	-32	-30	-29	N/A
12/31/2019	N/A	-18	-23	-19	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ACLX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ACLX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ACLX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ACLXDie Einnahmen des Unternehmens (22.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: ACLXDie Einnahmen des Unternehmens (22.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ACLX wird voraussichtlich in 3 Jahren unrentabel sein.

Arcellx Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 11%

Price target increased by 9.7% to US$105

Price target increased by 7.1% to US$89.67

Consensus revenue estimates increase by 21%

Consensus revenue estimates increase by 14%

Consensus revenue estimates increase by 11%

Recent updates

Consensus EPS estimates fall by 11%

Chief Financial Officer notifies of intention to sell stock

Price target increased by 9.7% to US$105

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Independent Director notifies of intention to sell stock

Price target increased by 7.1% to US$89.67

Now 20% overvalued after recent price rise

Chief Financial Officer notifies of intention to sell stock

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Massive 28% Price Jump

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$320k worth of stock

Consensus revenue estimates increase by 21%

We're Interested To See How Arcellx (NASDAQ:ACLX) Uses Its Cash Hoard To Grow

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 21% undervalued after recent price drop

Chief Medical Officer exercised options and sold US$990k worth of stock

Now 21% overvalued after recent price rise

A Look At The Fair Value Of Arcellx, Inc. (NASDAQ:ACLX)

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Now 21% undervalued after recent price drop

New major risk - Revenue and earnings growth

News Flash: Analysts Just Made A Sizeable Upgrade To Their Arcellx, Inc. (NASDAQ:ACLX) Forecasts

Consensus revenue estimates increase by 14%

Chief Financial Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%

Rainbows and Unicorns: Arcellx, Inc. (NASDAQ:ACLX) Analysts Just Became A Lot More Optimistic

Is Arcellx (NASDAQ:ACLX) A Risky Investment?

New major risk - Revenue and earnings growth

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Chief Medical Officer exercised options and sold US$818k worth of stock

Arcellx, Inc., Annual General Meeting, May 24, 2024

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 10%

Price target increased by 13% to US$75.92

Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 10.0% to US$72.27

Chairman of the Board recently sold US$2.4m worth of stock

New major risk - Revenue and earnings growth

Chairman of the Board notifies of intention to sell stock

Arcellx: Navigating The CAR T-Cell Revolution

Chairman of the Board recently sold US$1.6m worth of stock

Chairman of the Board notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Price target increased by 8.5% to US$65.18

Arcellx, Inc. Announces Continued Robust Long-Term Responses from its Cart-Ddbcma Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma At Ash

Need To Know: Analysts Are Much More Bullish On Arcellx, Inc. (NASDAQ:ACLX) Revenues

Arcellx, Inc. announced that it expects to receive $199.999991 million in funding from Gilead Sciences, Inc.

Price target increased by 9.5% to US$56.55

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 11%

Arcellx, Inc. Announces Oral Presentation for CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma At the 65th ASH Annual Meeting and Exposition

Consensus revenue estimates fall by 47%

Arcellx, Inc. Announces Partial Clinical Hold Lifted on Immagine-1 Phase 2 Clinical Program

Arcellx, Inc. Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

Chairman of the Board recently sold US$115k worth of stock

Consensus EPS estimates fall by 365%

Price target increased by 12% to US$47.56

Earnings Miss: Arcellx, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Price target increased by 9.2% to US$43.56

Chief Medical Officer notifies of intention to sell stock

Price target increased by 7.9% to US$42.33

Chief Medical Officer exercised options and sold US$404k worth of stock

Chief Medical Officer notifies of intention to sell stock

Arcellx, Inc. announced that it has received $100.000004 million in funding from Gilead Sciences, Inc.

Insider recently sold US$51k worth of stock